Trial Profile

A Single-Blind, Placebo-Control, Randomized Phase 2 Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease Lipomas

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 23 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CBL-514 (Primary)
Indications Adiposis dolorosa
Focus Adverse reactions; Therapeutic Use
Sponsors Caliway Biopharmaceuticals

Most Recent Events

17 Apr 2025 According to a Caliway Biopharmaceuticals media release, trial is currently ongoing and expected to complete patient recruitment by Q3 2025.
30 Oct 2024 Planned End Date changed from 3 Sep 2025 to 1 Nov 2025.
30 Oct 2024 Planned primary completion date changed from 3 Sep 2025 to 1 Aug 2025.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com